DKSH has signed a new partnership with ABclonal, a leading integrated solutions provider for biomedical research in Thailand.
Bangkok, January 27, 2023 – DKSH Business Unit Technology has signed an agreement with ABclonal, one of the leading companies in the global antibodies market, to provide integrated solutions for biomedical research. DKSH will provide sales, marketing, application support, and after-sales services across Thailand.
Based in Massachusetts, ABclonal is a dynamic and growing provider of high-quality biology research reagents, tools, and custom services with the aim of improving the quality of life science research for scientists around the world. The company focuses on four areas: antibodies and immunoassays, genomic research reagents, contact research organization (CRO) services, and instruments and consumables. DKSH will help ABclonal to penetrate the market and promote its products and services to customers in Thailand.
"DKSH has a systematic approach to market expansion and a strong business network in Thailand. Their strong expertise in application, marketing, and after-sales support makes them the best partner to help us expand our markets and achieve our growth goals,” said Evan Yang, District Supervisor, ABclonal.
Oliver Hammel, Vice President, Business Unit Technology, DKSH Thailand, commented: “The partnership with ABclonal helps strengthen our market position in scientific instrumentation. We are excited to introduce ABclonal’s innovative products to our customers.”